Skip to main content

Ortivus AB (publ) interim report for the period January – March 2023

2023-05-04 08:30

Ortivus initiates customer delivery projects in the Baltics

Highlights January – March 2023

  • Ortivus signs a framework agreement with East of England NHS Collaborative Procurement Hub regarding MobiMed ePR, creating new opportunities in the UK. The agreement means that all UK Ambulance Trusts can call-off electronic patient records – ePR solutions, from all qualified companies. The contract period is 2 years from the start date.
  • Ortivus signs a contract regarding the delivery of MobiMed ePR to the Estonian ambulance fleet. The contract has an order value of approximately 26 MSEK over a period of 5 years with a possible extension for another 5 years. The extension period also has an estimated order value of 26 MSEK.
  • Ortivus signs a framework agreement with Stockholm County Healthcare District (SLSO) regarding MobiMed Life, semi-automatic defibrillators. The customer will call-off units as need arises. The total order value for the entire framework agreement period, which is four years, amounts to a maximum of 2.4 MSEK.
  • Ortivus AB acquires approx. 10% of the company H&E Solutions AB, a Swedish technology company that has developed Evam – an operating system for emergency vehicles.

Significant events after end of the period

  • Ortivus qualifies for the NHS framework agreement covering MobiMed Life, which creates new opportunities in the UK.
  • Ortivus’ product range is further broadened via an asset purchase agreement of the vehicle control system FleetCtrl, which together with Ortivus’ other products form a competitive total solution for the future of healthcare.

January – march 2023

  • Net sales amounted to 28.0 (24.6) MSEK.
  • The gross margin amounted to 48% (47%).
  • EBITDA amounted to 0.2 (2.0) MSEK.
  • Earnings after tax per share before and after dilution amounted to 0.01 (0.04) SEK.
  • Operating cash flow before changes in working capital amounted to 1.5 (2.4) MSEK.
Jan-Mar 2023 Jan-Mar 2022 Jan-Dec 2022
Net sales (MSEK) 28.0 24.6 104.5
Gross margin (%) 48% 47% 47%
Operating profit (MSEK) 0.5 2.0 5.8
Operating margin (%) 2% 8% 6%
EBITDA (MSEK) 1.5 2.9 10.2

Get in touch

Empower your team with smarter tools

Join leading healthcare organisations that have already improved patient outcomes and reduced costs with Ortivus’ innovative out-of-hospital solutions.

Get contacted

Fill in the form and one of our sales representatives will contact you as soon as possible.

Required